Discoid lupus erythematosus (DLE) is a chronic dermatological disease that can lead to scarring, alopecia and dyspigmentation, if not properly treated. Actually, no drugs are specifically approved for the treatment of CLE, although the first-line therapy usually consists of photoprotection associated to topical or oral steroids, topical calcineurin inhibitors and hydroxychloroquine (HCQ). In cases of DLE refractory to these medications, many other agents have been employed, such as dapsone, methotrexate, azathioprine, cyclophosphamide, biologic drugs and Intravenous Immunoglobulin (IVIG). We described the case of a DLE patient resistant to combination therapy with steroid and HCQ who was successfully treated with cyclical IVIG therapy. The treatment with IVIG resulted rapidly effective with persistent efficacy and low rates of relapses, although more cycles of IVIG are needed to achieve a stable clinical remission. We also discussed the beneficial and promising effects of IVIG in patients with Cutaneous Lupus reporting the previously published data.
|Titolo:||Intravenous Immunoglobulins as a new opportunity to treat discoid lupus erythematosus: A case report and review of the literature|
|Citazione:||Tenti, S., Fabbroni, M., Mancini, V., Russo, F., Galeazzi, M., & Fioravanti, A. (2018). Intravenous Immunoglobulins as a new opportunity to treat discoid lupus erythematosus: A case report and review of the literature. AUTOIMMUNITY REVIEWS, 17(8), 791-795.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto:
|Intravenous Immunoglobulins as a new opportunity to treat discoid lupus erythematosus.pdf||PDF editoriale||NON PUBBLICO - Accesso privato/ristretto||Administrator Richiedi una copia|